TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7568633

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg EtOH
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 0.6 g/kg EtOH
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg EtOH
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 1.0 g/kg EtOH
Number of subjects: 3

Group type: COMPARATOR
Intervention: Baseline performance
Number of subjects: 3
Study: 2332569

Group type: EXPERIMENTAL
Intervention: Dipivefrin 0.1% eye drops
Number of subjects: 5

Group type: COMPARATOR
Intervention: Patch testing with individual components of Propine
Number of subjects: 5
Study: 6795164

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31651944

Group type: EXPERIMENTAL
Intervention: Mini-extracorporeal circulation (MECC)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting (OPCABG)
Number of subjects: 230
Study: 30308523

Group type: EXPERIMENTAL
Intervention: Bilateral suprazygomatic maxillary nerve blocks
Number of subjects: 114

Group type: COMPARATOR
Intervention: Bilateral infraorbital nerve blocks and bilateral greater and lesser palatine nerve blocks and nasopalatine nerve block
Number of subjects: 114
Study: 28187044

Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy (MIE)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Open esophagectomy
Number of subjects: 115
Study: 26246458

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day plus saxagliptin and metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus saxagliptin and metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25138183

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 240
Study: 22935227

Group type: EXPERIMENTAL
Intervention: Varicella vaccine in SLE patients (28 vaccinated)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Healthy controls (28 vaccinated)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Unvaccinated SLE group (26 unvaccinated)
Number of subjects: 54
Study: 19899831

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 17767456

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study: 15220251

Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg/day)
Number of subjects: 40
Study: 11242149

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) 300 mg twice a day until labour, 600 mg at the beginning of labour, and 300 mg twice a day for 7 days post-partum (n = 23)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo (n = 32)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) (n = 47)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo (n = 70)
Number of subjects: 172
Study: 9586595

Group type: EXPERIMENTAL
Intervention: α‐adrenoceptor‐blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5‐α‐reductase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More uroselective α‐blockers
Number of subjects: 0
Study: 8147676

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs (specific drugs not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antihypertensive agents (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Questionnaires for assessing sexual dysfunction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Research protocols using a double-blind, placebo-controlled design
Number of subjects: 0
Study: 2703283

Group type: EXPERIMENTAL
Intervention: Newly developed 'unisex' regression equations for pulmonary function prediction
Number of subjects: 374

Group type: COMPARATOR
Intervention: Commonly recommended pulmonary function prediction equations
Number of subjects: 374
Study: 31183902

Group type: EXPERIMENTAL
Intervention: Digital workflow (test group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional workflow (control group)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both workflows
Number of subjects: 31
Study: 28581693

Group type: EXPERIMENTAL
Intervention: Pink abutment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gray abutment
Number of subjects: 40
Study: 25224097

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (men only)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Usual care (men only)
Number of subjects: 196
Study: 23954313

Group type: EXPERIMENTAL
Intervention: CRF‐R1 antagonist (GW876008) 20 mg or 200 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CRF‐R1 antagonist (GW876008)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 21476113

Group type: EXPERIMENTAL
Intervention: Supplemental inspired oxygen for the first 2 days after surgery
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control group (no supplemental oxygen)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Supplemental inspired oxygen for the first 2 days after surgery (isolated groin incisions)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control group (no supplemental oxygen, isolated groin incisions)
Number of subjects: 274
Study: 18057049

Group type: EXPERIMENTAL
Intervention: Mechanical pleural abrasion (group A)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Apical pleurectomy (group B)
Number of subjects: 208
Study: 16542503

Group type: EXPERIMENTAL
Intervention: Oral clodronate (1,600 mg/day)
Number of subjects: 1069
Study: 12674267

Group type: EXPERIMENTAL
Intervention: Interpersonal cognitive problem-solving
Number of subjects: 39

Group type: COMPARATOR
Intervention: Language workshop
Number of subjects: 39
Study: 10741706

Group type: EXPERIMENTAL
Intervention: 45 mg/m2 ATRA once daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 90 mg/m2 ATRA once daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 150 mg/m2 ATRA once daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 15 mg/m2/day ATRA every 8 h
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: ATRA pharmacokinetics
Number of subjects: 21
Study: 9093241

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8463519

Group type: EXPERIMENTAL
Intervention: 24% protein (61 g protein/L; n = 15)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 14% protein (37 g protein/L; n = 13)
Number of subjects: 28
Study: 3768576

Group type: EXPERIMENTAL
Intervention: Intensive treatment (one or more of a selection of individually tailored, cognitive‐behavioural therapies lasting an average of 9.1 sessions)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Minimal treatment (three or four sessions' assessment and advice)
Number of subjects: 37
Study: 30298859

Group type: EXPERIMENTAL
Intervention: 1.23% acidulated phosphate fluoride gel (APG)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 2% neutral fluoride gel (NFG)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 1.23% acidulated fluoride mousse (AFM)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (5% Duraphat, DFV)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Untreated (C control)
Number of subjects: 25
Study: 28341592

Group type: EXPERIMENTAL
Intervention: AlloMax
Number of subjects: 30

Group type: COMPARATOR
Intervention: AlloDerm RTU
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AlloDerm RTU and AlloMax
Number of subjects: 30
Study: 26297933

Group type: EXPERIMENTAL
Intervention: Integra Dermal Regeneration Template (IDRT); n = 154
Number of subjects: 307

Group type: COMPARATOR
Intervention: 0.9% sodium chloride gel (control); n = 153
Number of subjects: 307
Study: 23632737

Group type: EXPERIMENTAL
Intervention: DSS Group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 150
Study: 23661841

Group type: EXPERIMENTAL
Intervention: Combined supplement of 40 mg zinc as zinc gluconate and 40 mg iron as ferrous sulphate
Number of subjects: 100

Group type: COMPARATOR
Intervention: 40 mg elemental iron as ferrous sulphate (Control)
Number of subjects: 100
Study: 19301937

Group type: EXPERIMENTAL
Intervention: 5% lidocaine medicated plaster
Number of subjects: 146

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 146
Study: 17522789

Group type: EXPERIMENTAL
Intervention: Diclofenac low-dose infusion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Extemporaneous boluses of NSAIDs (CTRL)
Number of subjects: 22
Study: 12665701

Group type: EXPERIMENTAL
Intervention: Risedronate 30 mg once weekly with vitamin D 400 iu daily and 1200 mg of calcium daily
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Risedronate 30 mg once weekly
Number of subjects: 150
Study: 11059477

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8781308

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 1532684

Group type: EXPERIMENTAL
Intervention: Orthodontic cement VP 862 (containing fluoride)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Heliosit‐Orthodontic (no fluoride)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluoride release from fluoride adhesive in water
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluoride release in human saliva at pH 7
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluoride release in saliva at pH 4
Number of subjects: 10
Study: 6370428

Group type: EXPERIMENTAL
Intervention: vincristine-prednisone alternating with cytarabine-cyclophosphamide (Arm B)
Number of subjects: 347

Group type: COMPARATOR
Intervention: vincristine-prednisone (Arm A)
Number of subjects: 347
Study: 2858709

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg twice daily for two years
Number of subjects: 1285

Group type: COMPARATOR
Intervention: Untreated control group with systemic therapy reserved until the time of relapse
Number of subjects: 1285
Study: 30395350

Group type: EXPERIMENTAL
Intervention: One-level reduction in WHO drinking risk level
Number of subjects: 1142

Group type: EXPERIMENTAL
Intervention: Two-level reduction in WHO drinking risk level
Number of subjects: 1142
Study: 26798655

Group type: EXPERIMENTAL
Intervention: Intervention practices (DR screening and monitoring via telehealth)
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Control practices (usual care)
Number of subjects: 1024
Study: 25034862

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg every 3 weeks
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 3 weeks
Number of subjects: 173
Study: 22336221

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m² every 21 days)
Number of subjects: 663

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 663
Study: 20090319

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 150

Group type: COMPARATOR
Intervention: Aspirin (ASA)
Number of subjects: 150
Study: 18346537

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 16845252

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg plus Ramipril 2.5 mg daily
Number of subjects: 20
Study: 14557145

Group type: EXPERIMENTAL
Intervention: High-frequency left-sided repetitive transcranial magnetic stimulation (HFL-TMS) applied daily for 4 weeks (20 5-second trains at 10 Hz)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-frequency right-sided repetitive transcranial magnetic stimulation (LFR-TMS) applied daily for 4 weeks (five 60-second trains at 1 Hz)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham stimulation (coil angled at 45 degrees from the scalp)
Number of subjects: 60
Study: 10945509

Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.1% ophthalmic solution
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ketotifen fumarate 0.025% ophthalmic solution
Number of subjects: 32
Study: 8883115

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg calcium as calcium citrate malate per day)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg calcium as calcium citrate malate per day) in subjects with above-median Tanner scores
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo in subjects with above-median Tanner scores
Number of subjects: 112
Study: 1576854

Group type: EXPERIMENTAL
Intervention: Training group (n = 22)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 38
Study: 3880688

Group type: EXPERIMENTAL
Intervention: Indomethacin sustained-release (ISR) oral preparation once a day at varying dosing times (8 a.m., noon, and 8 p.m.)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Indomethacin sustained-release (ISR) oral preparation at 8 a.m.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Indomethacin sustained-release (ISR) oral preparation at 8 p.m.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Indomethacin sustained-release (ISR) oral preparation with evening dosing
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Indomethacin sustained-release (ISR) oral preparation with morning or noon dosing
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Indomethacin sustained-release (ISR) oral preparation
Number of subjects: 66
Study: 31136263

Group type: EXPERIMENTAL
Intervention: Autologous PRP gel (3.5 ml ± 1.5 ml) injected at bone-tendon interface
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no PRP gel)
Number of subjects: 69
Study: 29065364

Group type: EXPERIMENTAL
Intervention: Behavioral activation intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-intervention group (control)
Number of subjects: 40
Study: 26465137

Group type: COMPARATOR
Intervention: Extensive casein hydrolyzate (eHF-C)
Number of subjects: 2252

Group type: COMPARATOR
Intervention: Partial whey hydrolyzate (pHF-W)
Number of subjects: 2252

Group type: COMPARATOR
Intervention: Extensive whey hydrolyzate (eHF-W)
Number of subjects: 2252

Group type: EXPERIMENTAL
Intervention: Standard cow's milk formula (CMF)
Number of subjects: 2252
Study: 25186834

Group type: EXPERIMENTAL
Intervention: Loading-dose rosuvastatin 40 mg given 4 h before PCI
Number of subjects: 143

Group type: COMPARATOR
Intervention: Conventional-dose rosuvastatin 10 mg given 4 h before PCI
Number of subjects: 143
Study: 22480536

Group type: EXPERIMENTAL
Intervention: Patients with bipolar disorder excluded from trials due to medical conditions
Number of subjects: 10
Study: 20660279

Group type: EXPERIMENTAL
Intervention: Blueberry supplementation (50 g freeze-dried blueberries, approximately 350 g fresh blueberries)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (960 mL water)
Number of subjects: 48
Study: 18778199

Group type: EXPERIMENTAL
Intervention: Peg‐Interferon alpha‐2a (180 microg weekly subcutaneously)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Peg‐Interferon alpha‐2b (1.5 microg/kg weekly subcutaneously)
Number of subjects: 143
Study: 15947736

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxic tent (NH)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal ambient environment (BL)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normobaric normoxic tent (NN)
Number of subjects: 8
Study: 12764339

Group type: EXPERIMENTAL
Intervention: Phenylephrine in one eye
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sterile water in the other eye
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Measurement of pupillary dilation
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Gestalt judgment of pupillary dilation
Number of subjects: 102
Study: 11783239

Group type: EXPERIMENTAL
Intervention: Taozhi Zhipu Mixture (TZM)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Control group (no TZM)
Number of subjects: 396
Study: 8896482

Group type: EXPERIMENTAL
Intervention: Iloprost regimen (intravenous at the beginning of the operation and three daily 6-hour infusions postoperatively, with an intragraft injection at completion of the bypass)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Iloprost regimen
Number of subjects: 528

Group type: COMPARATOR
Intervention: Iloprost regimen and Placebo
Number of subjects: 528
Study: 2053784

Group type: EXPERIMENTAL
Intervention: Nebulised acidic salbutamol solution
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo of equal acidity (pH 3.9)
Number of subjects: 34
Study: 6406443

Group type: EXPERIMENTAL
Intervention: Bupropion (Wellbutrin)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Amitriptyline (Elavil, Endep)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 30957534

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 64
Study: 28677349

Group type: EXPERIMENTAL
Intervention: HBB 20 mg
Number of subjects: 299

Group type: COMPARATOR
Intervention: Anisodamine 10 mg
Number of subjects: 299
Study: 26582355

Group type: EXPERIMENTAL
Intervention: Computer-assisted operation method for minimal-invasive total hip replacement (CAS FF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional total hip replacement (CON)
Number of subjects: 60
Study: 23383973

Group type: EXPERIMENTAL
Intervention: Xilei-san enema
Number of subjects: 35

Group type: COMPARATOR
Intervention: Dexamethasone enema
Number of subjects: 35
Study: 21306830

Group type: EXPERIMENTAL
Intervention: Baseline positive expectancies
Number of subjects: 5782

Group type: EXPERIMENTAL
Intervention: Baseline depressed mood
Number of subjects: 5782

Group type: EXPERIMENTAL
Intervention: Positive expectancies
Number of subjects: 5782

Group type: EXPERIMENTAL
Intervention: Depressed mood
Number of subjects: 5782
Study: 19682118

Group type: EXPERIMENTAL
Intervention: Influenza vaccination of staff
Number of subjects: 40

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 40
Study: 17287478

Group type: EXPERIMENTAL
Intervention: 45 mg interleukin-12/23 monoclonal antibody
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: 90 mg interleukin-12/23 monoclonal antibody
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: four weekly 45 mg interleukin-12/23 monoclonal antibody
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: four weekly 90 mg interleukin-12/23 monoclonal antibody
Number of subjects: 320

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: interleukin-12/23 monoclonal antibody
Number of subjects: 320
Study: 15111188

Group type: EXPERIMENTAL
Intervention: Sealant
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control
Number of subjects: 161
Study: 11700905

Group type: EXPERIMENTAL
Intervention: Semantic neighborhood defined by associations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semantic neighborhood defined by global co-occurrences
Number of subjects: 0
Study: 9228873

Group type: EXPERIMENTAL
Intervention: FES leg cycle exercise (FES-LCE)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hybrid exercise training
Number of subjects: 11
Study: 8424383

Group type: EXPERIMENTAL
Intervention: High-omega 6 polyunsaturated fatty acid diet (8.4 en% polyunsaturated fatty acids, 8.3 en% linoleic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower-omega 6 polyunsaturated fatty acid diet (3.1 en% polyunsaturated fatty acids, 3.0 en% linoleic acid)
Number of subjects: 0
Study: 3301120

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (SK) 1‐h infusion of 1,500,000 IU
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (SK)
Number of subjects: 64
Study: 29314866

Group type: EXPERIMENTAL
Intervention: 900 mg/day spearmint extract
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 26259895

Group type: EXPERIMENTAL
Intervention: Injectable contraception
Number of subjects: 2018

Group type: COMPARATOR
Intervention: Oral contraceptive pills
Number of subjects: 2018

Group type: COMPARATOR
Intervention: Condoms
Number of subjects: 2018

Group type: COMPARATOR
Intervention: Other methods (intrauterine device, traditional methods, natural methods)
Number of subjects: 2018
Study: 25933511

Group type: EXPERIMENTAL
Intervention: LDB-CPR
Number of subjects: 912

Group type: COMPARATOR
Intervention: M-CPR
Number of subjects: 912
Study: 24124961

Group type: EXPERIMENTAL
Intervention: Insulin degludec and insulin aspart (IDegAsp)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 112
Study: 20110274

Group type: EXPERIMENTAL
Intervention: Iron treatment with follow-up visits to provide IDA education
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Iron treatment with no follow-up
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control
Number of subjects: 189
Study: 19568702

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.4% q.i.d.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Bromfenac 0.09% b.i.d.
Number of subjects: 61
Study: 17826496

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 643

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study: 15156950

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy followed by standard level I and II axillary dissection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy without dissection unless metastatic disease is noted
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Completion axillary dissection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 11532888

Group type: EXPERIMENTAL
Intervention: Low-frequency responding during 'Go/No-go' task (response inhibition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-frequency responding during 'oddball' task (target detection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-frequency responding during two-alternative forced-choice task (response selection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response inhibition condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trials with errors committed
Number of subjects: 0